

Charity registration number: 1164238

Action Kidney Cancer

Annual Report and Financial Statements

for the Year Ended 31 October 2023

Action Kidney Cancer

Contents (continued)

Reference and Administrative Details	1
Trustees' Report	2 to 7
Statement of Trustees' Responsibilities	8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11
Notes to the Financial Statements	12 to 19

Action Kidney Cancer

Reference and Administrative Details

Chairman	A Thomas
Trustees	A Thomas J Larkin J Pym A Fielding S Turajlic
Charity Registration Number	1164238
Principal Office	11th Floor 3 Piccadilly Manchester M1 3BN
Independent Examiner	Stockdale Accountants Ltd St Ingungger Offices Lanivet Bodmin Cornwall PL30 5HS

ACTION KIDNEY CANCER (Action Kidney Cancer is the working name of 'Kidney Cancer Support Network')

Trustees Report for the year ended 31st October 2023

The Trustees present their report together with the financial statement for the year ended 31st October 2023. In preparing this report, the Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "accounting and reporting by charities" issued in March 2005.

Registered charity number: 1164238 in England Wales, SC051330 in Scotland

Status: Charitable Incorporated Organisation (CIO) Incorporated 3 November 2015 England Wales

Status: Charitable Incorporated organisation (CIO) incorporated 7 October 2021 Scotland

Principal and registered address:

ACTION KIDNEY CANCER
Kidney Cancer Support Network,
11th Floor, 3 Piccadilly Place
Manchester M1 3BN

Trustees

Mr Andy Thomas – Chair
Professor James Larkin
Mr Jonathan Pym
Professor Samra Turajlic
Ms. Alison Fielding

Structure, governance, and management.

ACTION KIDNEY CANCER began its work as a voluntary support organisation in 2006. It was registered as a formal charitable incorporated organisation (CIO) on the 3 November 2015 and the charity is managed according to its governing documents dated 3 November 2015.

The charity underwent a complete rebranding during in 2021 and is now known by its working name **ACTION KIDNEY CANCER**.

Where there is a requirement for new Trustees, they will be identified and appointed by the current Trustees. The ACTION KIDNEY CANCER management team is responsible for the induction of any new Trustees, and this will involve a briefing about Trustee responsibilities, the governing document, and the adopted operating policies and procedures of the charity. All Trustees provide their services to the charity on a voluntary unpaid basis.

The Trustees delegate day-to-day responsibility for the running of the charity to the management team who are accountable to the Trustees and report to the Trustees throughout the year as required and at regular Trustee meetings.

The Trustees have a duty to identify and review all risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error. The Trustees regularly review the risks that the charity may face, and the Trustees will continue to monitor the risks associated with its activities and continue to be vigilant as to other risks that might be associated with a charity providing support services to people affected by kidney cancer.

The Trustees have agreed and adopted a series of operating policies to ensure the charity runs smoothly and complies with all charity commission requirements and legal responsibilities. The operating policies are reviewed every two years and are available by written request to the ACTION KIDNEY CANCER management team. Some policies are available via the ACTION KIDNEY CANCER website.

The Trustees declare as part of this annual return, that there are no serious incidents or other matters the Trustees should have reported to the Charity Commission.

Charity objectives and activities

To promote and protect the physical and mental health of patients with kidney cancer in the United Kingdom by:

1. The provision of information, support, education and practical advice to kidney cancer patients, their families, and their carers
2. To advance the education and awareness of all matters relating to kidney cancer with the general public
3. Promoting and supporting research projects into the causes, diagnosis, prevention, treatment, and cure of kidney cancer and disseminating the results of such research.

The Trustees meet a minimum of once a year, to discuss, agree and record charitable activities, strategy, funding priorities, and operating policies, including risk management. Project meetings are held throughout the year as required and/or as requested by the Trustees or management team.

Public benefit

The Trustees confirm that they have referred to the guidance provided by the charity commission's general guidance and advice on public benefit. In planning all activities including financial policies, the trustees confirm they have complied with the duty in section 17(5) of the 2011 Charities Act and the Trustees are satisfied that all charitable activities during the year are for the benefit of the public.

Achievements and performance

ACTION KIDNEY CANCER is a patient and carer led kidney cancer charity with a unique perspective and understanding of the needs of kidney cancer patients, carers, and their families. ACTION KIDNEY CANCER provides information, support, and advocacy to anyone affected by kidney cancer and seeks to educate and inform the public in all aspects of kidney cancer.

The year ending 31 October 2023 was a very busy and productive time for the charity. The aftermath of the COVID 19 pandemic is still having a significant impact on the ability of the NHS to meet cancer waiting time standards and this is having a severe impact on our patient community. Our management team continue to work hard together, reaching out and supporting kidney cancer patients and carers. The charity provides information about treatment options, updates, and advice for patients about NHS waiting lists and delays, and how to access treatment options and care services. The support cases can be complex, they are time-consuming and require a personalised approach, but we know that recently diagnosed patients are particularly vulnerable and trying to

negotiate their way around the complexities of the NHS system, adds significantly to their worries and fears.

We are told that the pandemic is still affecting the ability of the NHS to meet the demand for its services. Patients and their families bear the brunt of the delays and patients report long wait times for diagnosis and lengthy waits for surgery. There are delays for routine scans and the wait times for test results have lengthened up to and sometimes beyond, 6 weeks. Because of this, kidney cancer patients and their families turn to the charity for support and practical advice about how to navigate the complexities of the NHS system in order to get timely appointments, scan results and 2nd opinions.

We are reliant on and thankful for the work of the ACTION KIDNEY CANCER management team who have worked long hours throughout the year to support each other in addition to providing bespoke support and advice to individual patients and family members within our online community forum, via our freephone helpline and via peer-to-peer email service and zoom/video links.

In addition, we provide regular daily kidney cancer news, research, updates via our website and social media channels and we continue to provide practical information about the COVID 19 vaccination programme on our website for the public and patients.

Core activities.

***Website.** Our new website is updated daily with kidney cancer news, research, and campaigning updates. We continue to add and review content on a planned basis including a formal review of all patient information, clinical information, and policy documents. We are preparing to apply for the Health Information Policy for PIF Tick accreditation to increase the credibility of our patient resources.

*** Projects 2022/23** In addition to our normal activities, we aim to produce several patient focused projects each year.

The Renal Oncology Nurse Network is one such project: following a talk and presentation at a nursing conference by management team member Karen McNee, we were approached to explore the feasibility of creating a renal cancer oncology nurse network with the aim of sharing best practices, providing up-to-date news and research, and to work in partnership with the nurses to create a depository of renal cancer information and resources. The aim is to provide admin support for kidney cancer oncology nurses in their work with kidney cancer patients. We now have over 50 kidney cancer nurses in our Renal Oncology Nurse Network (RONN's), and many have received our literature for their clinics. We held a successful inaugural online meeting on the 18th October 2023 and have plans for a rolling programme of events over the coming years.

We continued to add to our library of video interviews with expert clinicians and healthcare professionals designed to answer questions raised from within the community. The expert videos involve the charity management team interviewing clinicians and nurses with experience and knowledge of treatments and caring for patients with kidney cancer.

We were approached by Glasgow University to assist with writing 2 modules (50% of the course) for the RCC4Nurses online training course. This course has been well received and our medical writer Sharon Deveson Kell is mentioned as a collaborative author of this work.

As part of our international work, ACTION KIDNEY CANCER project managed and authored a comprehensive Decision Aid for patients considering participating in a clinical trial. The booklet, called "My Treatment, My Choice - A decision aid to help people decide whether to take part in a clinical trial for kidney cancer" was published by IKCC (www.ikcc.org) in April 2023 and is freely

available to patients and HCPs around the world for anyone wanting to understand more about patient participation in kidney cancer clinical trials.

*** Patient involvement.** We have been very proactive with our cancer advocacy organisation partners, such as Cancer 52, Cancer Research UK, Macmillan Cancer Relief, Coalition for Reducing Bureaucracy in Clinical Trials, Independent Cancer Patient Voice (ICPV), and the ABPI Patient Organisation Forum. Advocacy on behalf of the kidney cancer community is a vital part of our work and ACTION KIDNEY CANCER is recognised nationally and internationally as a genuine patient-led charity providing a strong patient focussed voice. We continue to campaign publicly for meaningful patient involvement in all aspects of patient treatment and care, research, and survivorship.

*** Clinical trials.** We continue to work with the scientific community and research establishments across the country to help improve geographical spread, recruitment, and retention of kidney cancer patients into clinical trials around the UK. We are frequently involved in clinical trial design and data management committees; we are called on to review and/or help write clinical trial Patient Information Sheets and clinical trial protocols, and review patient videos for clinical trials. As patient experts and representatives, we work in partnership with leading renal cancer clinicians, nurses, and members of the scientific community towards better care and treatment options and ultimately a cure for kidney cancer.

We have continued to invest time and funds in our unique kidney cancer clinical trials database on our website. The clinical trials database is a fully functional searchable database written in patient-friendly language and complemented with a full glossary and a range of patient educational resources about clinical trials, both written and video format. We provide support and work with individual kidney cancer patients to help find suitable clinical trials which patients can then print off and discuss with their hospital team.

Over the year, we were able to play a leading role in several campaigns and took the opportunity to provide a strong patient voice into several nationally important pieces of work: including RAMPART, REFINE, TRACERX, OPTIC and EQUATOR clinical trial groups.

We belong to the Coalition for Reducing Bureaucracy in Clinical Trials where we have a role as lead for the “informed consent” working group.

***Patient support.** We provide the only “peer to peer” managed kidney cancer helpline in the UK. We provide a friendly yet knowledgeable point of contact for patients and carers to discuss their concerns in an open, impartial, and non-judgemental way. Our aim is to provide patients with an individual and personal service, providing quality evidence-based information and personal advocacy.

Our private “peer to peer” online discussion forum has an active membership of over 1400 kidney cancer patients, carers, and family members. Our support forum is available 24/7 and is a unique support service managed and moderated by expert patients, caregivers, and advocates. This is a busy yet welcoming online forum that offers evidence-based information, shared patient experiences and general patient and carer support. Our discussion forum regularly records over 7000 comments & interactions every month covering all aspects of living with kidney cancer such as sharing emotional and practical issues, including side effects management, diet and well-being, family relationships, financial and work issues, survivorship, and bereavement and loss.

***Campaigning.** ACTION KIDNEY CANCER participated in the very successful International World Kidney Cancer Day in 2023. We led the UK campaign around a theme of “we need to talk about living with kidney cancer” “providing expert patient videos and taking part in the global symposium.

The charity was part of the policy team that led the Big Cancer52 Conversation. Action Kidney Cancer took the lead role for the “access to clinical trials” working group.

***Communication.** We continue to produce our valuable professionally written quarterly ACTION KIDNEY CANCER newsletter updating our community of patient, carers, and healthcare professionals with the latest kidney cancer research and reviews, interviews, and patient activities.

We have written & distributed patient-friendly highlights from the main oncology conferences in Europe (ESMO and the EAU) and North America (ASCO and ASCO GU) and the IKCC Global Kidney Cancer Summit report. Keeping the patient community up to date with current research is an important area of our work.

*** Partnership working.** We have continued to provide an expert kidney cancer patient perspective at various online meetings, webinars and virtual and face-to-face conferences organised by the National Health Service (NHS), International Kidney Cancer Coalition (IKCC), pharmaceutical companies, National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) and the National Kidney Cancer Audit.

Action Kidney Cancer are members of the following organisations: Welsh Cancer Alliance, Scottish Cancer Coalition and Scottish Cross Party Group for cancer, Northern Ireland Cancer Coalition. We attend face-to-face and online meetings to ensure the kidney cancer patient perspective is heard.

We collaborate with Cancer52, One Cancer Voice and All.Can on policy issues such as tackling inequalities, improving the cancer journey, reducing inefficiencies in the healthcare system, the Major Conditions Strategy, and early diagnosis and prevention of cancer together with raising awareness of AMR and the anti-smoking lobby.

We work in partnership with the ABPI and took part in their conference on real world data. We attend regular meetings as a member of the ABPI patient involvement committee to ensure the patient voice is always heard in discussions with our pharmaceutical industry partners.

***Fundraising.** During the year, management team member Karen McNee oversaw several successful fundraising events including a parachute jump in Wales, a musical evening, and our very successful yearly event organised by management team member Steve Pointon and his family, the Northern Soul two-day dance event. We continue to promote the virtual Lands’ End to John O’Groats project, the Mad Hatters Tea Party and our “Gift a Heart “Campaign continues to be successful. Our cash collections remain strong despite a difficult economic climate. We also work in partnership with Project Flutter providing Butterfly Bags and comfort cushions to kidney cancer patients around the country.

*** NICE and SMC Health Technology Appraisals and Consultations** We have continued our clear mission to provide evidence based, well researched, patient submissions to health technology appraisals (HTA) related to kidney cancer drugs and the care of kidney cancer patients. We have provided expert patient statements at HTA committee meetings of NICE.

We attended the NICE committee meetings for the following appraisals and recommended expert clinicians and expert patients.

- o belzutifan for VHL
- o RCC patient pathway pilot
- o cabozantinib/nivolumab
- o adjuvant pembrolizumab.

In addition, we attended the SMC committee meetings and PACE meetings and provided written submissions and recommended clinical and patient experts for the following SMC health technology appraisals:

- o belzutifan for VHL
- o cabozantinib/nivolumab
- o adjuvant pembrolizumab.

We also provided a submission to the National Cancer Medicines Advisory Group (NCMAG) for sunitinib and pazopanib to be used off label, sunitinib was approved.

We are stakeholders and consultees for the NICE Kidney Cancer Guidelines and Rose Woodward is a lay member on the NICE Kidney Cancer Guidelines Committee.

Financial review


Along with many other charities, the economic recession has affected our fundraising activities. People within the patient community have been hit especially hard by inflation coming so quickly after the problems caused by the pandemic. Once again, we been able capitalise on our excellent reputation for meaningful patient involvement and medical writing which, together with grants and donations have provided the income which allows us to provide our wide range of patient support services and to look at ways of increasing the support we make available to patients.

During the financial year ending 31st October 2023, ACTION KIDNEY CANCER achieved an income of £134,698 which considering the current financial climate was a good result. Our management accountant works closely with our charity accountants Messrs. Stockdale Accountants with oversight from the Trustees. As part of good governance, the Action Kidney Cancer Trustees have recommended an amount of not less than 12 months core costs, be allocated to charity reserves to ensure the future sustainability of the charity is secured. Financial prudence dictates that we place these reserves in a separate bank account.

In 2023 we were able to access industry grants which have enabled us to achieve the charity aims and objectives; as the charity's reputation grows, we have supported more patients and families than ever before and received an increased number of helpline calls for support. Alongside vital policy work, the charity has maintained its focus on practical patient support, providing patients and families with up-to-date, evidence-based information and we continue to raise awareness and increase understanding about kidney cancer at a local, national, and international level whenever the opportunity arises.

The Trustees and the management team would like to express their sincere thanks and appreciation to all the volunteers and supporters who have helped us to maintain much needed services to the community in such challenging times. Without the wonderful support from our community and volunteers, we would not be able to do what we do.

Signed



Dated: 12th July 2024

Mr Andy Thomas – Chair of Trustees, ACTION KIDNEY CANCER

Action Kidney Cancer

Statement of Trustees' Responsibilities

The trustees are responsible for preparing the trustees' report and the financial statements in accordance with the United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and applicable law and regulations.


The law applicable to charities requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008, and the provisions of the constitution. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charity on 12/01/24 and signed on its behalf by:



A Thomas
Chairman and trustee

Action Kidney Cancer

Independent Examiner's Report to the trustees of Action Kidney Cancer

I report to the trustees on my examination of the accounts of Action Kidney Cancer for the year ended 31 October 2023.

Responsibilities and basis of report

As the charity trustees of Action Kidney Cancer you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').


I report in respect of my examination of the Action Kidney Cancer's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of Action Kidney Cancer as required by section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.


.....
Hayley Hall
FMAAT

St Ingungger Offices
Lanivet
Bodmin
Cornwall
PL30 5HS

Date: 12/07/24

Action Kidney Cancer

Statement of Financial Activities for the Year Ended 31 October 2023

	Note	Unrestricted funds £	Total 2023 £
Income and Endowments from:			
Donations and legacies		104,633	104,633
Other income		<u>30,064</u>	<u>30,064</u>
Total income		<u>134,697</u>	<u>134,697</u>
Expenditure on:			
Charitable activities		<u>(100,582)</u>	<u>(100,582)</u>
Total expenditure		<u>(100,582)</u>	<u>(100,582)</u>
Net income		<u>34,115</u>	<u>34,115</u>
Net movement in funds		34,115	34,115
Reconciliation of funds			
Total funds brought forward		<u>254,709</u>	<u>254,709</u>
Total funds carried forward	11	<u>288,824</u>	<u>288,824</u>
	Note	Unrestricted funds £	Total 2022 £
Income and Endowments from:			
Donations and legacies		106,704	106,704
Other income		<u>30,371</u>	<u>30,371</u>
Total income		<u>137,075</u>	<u>137,075</u>
Expenditure on:			
Charitable activities		<u>(87,212)</u>	<u>(87,212)</u>
Total expenditure		<u>(87,212)</u>	<u>(87,212)</u>
Net income		<u>49,863</u>	<u>49,863</u>
Net movement in funds		49,863	49,863
Reconciliation of funds			
Total funds brought forward		<u>204,846</u>	<u>204,846</u>
Total funds carried forward	11	<u>254,709</u>	<u>254,709</u>

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2022 is shown in note 11.

The notes on pages 12 to 19 form an integral part of these financial statements.

Action Kidney Cancer
(Registration number: 1164238)
Balance Sheet as at 31 October 2023

	Note	2023 £	2022 £
Fixed assets			
Tangible assets	7	-	243
Current assets			
Debtors	8	20,645	19,503
Cash at bank and in hand	9	<u>275,489</u>	<u>238,695</u>
		296,134	258,198
Creditors: Amounts falling due within one year	10	<u>(7,310)</u>	<u>(3,732)</u>
Net current assets		<u>288,824</u>	<u>254,466</u>
Net assets		<u>288,824</u>	<u>254,709</u>
Funds of the charity:			
Unrestricted income funds			
Unrestricted funds		<u>288,824</u>	<u>254,709</u>
Total funds	11	<u>288,824</u>	<u>254,709</u>

The financial statements on pages 10 to 19 were approved by the trustees, and authorised for issue on 12/07/24 and signed on their behalf by:

Andy Thomas

A Thomas
Chairman and trustee

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2023

1 Accounting policies

Statement of compliance

The financial statements have been prepared in accordance with the second edition of the Charities Statement of Recommended Practice issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

Basis of preparation

Action Kidney Cancer meets the definition of a public benefit entity under FRS 102. The accounts (financial statements) have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern.

Income and endowments

Voluntary income including donations, gifts, legacies and grants that provide core funding or are of a general nature is recognised when the charity has entitlement to the income, it is probable that the income will be received and the amount can be measured with sufficient reliability.

Donations and legacies

Donations and legacies are recognised on a receivable basis when receipt is probable and the amount can be reliably measured.

Grants receivable

Grants are recognised when the charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2023 (continued)

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Tangible fixed assets

Individual fixed assets costing £100.00 or more are initially recorded at cost.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the charity will not be able to collect all amounts due according to the original terms of the receivables.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2023 (continued)

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Statement of Financial Activities over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the charity has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2023 (continued)

Debt instruments

Debt instruments which meet the following conditions are subsequently measured at amortised cost using the effective interest method:

(a) The contractual return to the holder is (i) a fixed amount; (ii) a positive fixed rate or a positive variable rate; or (iii) a combination of a positive or a negative fixed rate and a positive variable rate.

(b) The contract may provide for repayments of the principal or the return to the holder (but not both) to be linked to a single relevant observable index of general price inflation of the currency in which the debt instrument is denominated, provided such links are not leveraged.

(c) The contract may provide for a determinable variation of the return to the holder during the life of the instrument, provided that (i) the new rate satisfies condition (a) and the variation is not contingent on future events other than (1) a change of a contractual variable rate; (2) to protect the holder against credit deterioration of the issuer; (3) changes in levies applied by a central bank or arising from changes in relevant taxation or law; or (ii) the new rate is a market rate of interest and satisfies condition (a).

(d) There is no contractual provision that could, by its terms, result in the holder losing the principal amount or any interest attributable to the current period or prior periods.

(e) Contractual provisions that permit the issuer to prepay a debt instrument or permit the holder to put it back to the issuer before maturity are not contingent on future events, other than to protect the holder against the credit deterioration of the issuer or a change in control of the issuer, or to protect the holder or issuer against changes in levies applied by a central bank or arising from changes in relevant taxation or law.

(f) Contractual provisions may permit the extension of the term of the debt instrument, provided that the return to the holder and any other contractual provisions applicable during the extended term satisfy the conditions of paragraphs (a) to (c).

Debt instruments that are classified as payable or receivable within one year on initial recognition and which meet the above conditions are measured at the undiscounted amount of the cash or other consideration expected to be paid or received, net of impairment.

With the exception of some hedging instruments, other debt instruments not meeting these conditions are measured at fair value through profit or loss.

Commitments to make and receive loans which meet the conditions mentioned above are measured at cost (which may be nil) less impairment.

Investments

Investments in non-convertible preference shares and non-puttable ordinary or preference shares (where shares are publicly traded or their fair value is reliably measurable) are measured at fair value through profit or loss. Where fair value cannot be measured reliably, investments are measured at cost less impairment.

Investments in subsidiaries and associates are measured at cost less impairment. For investments in subsidiaries acquired for consideration including the issue of shares qualifying for merger relief, cost is measured by reference to the nominal value of the shares issued plus fair value of other consideration. Any premium is ignored.

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2023 (continued)

Derivative financial instruments

The charity uses derivative financial instruments to reduce exposure to foreign exchange risk and interest rate movements. The charity does not hold or issue derivative financial instruments for speculative purposes.

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to their fair value at each reporting date. The resulting gain or loss is recognised in statement of financial activities immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in statement of financial activities depends on the nature of the hedge relationship.

Fair value measurement

The best evidence of fair value is a quoted price for an identical asset in an active market. When quoted prices are unavailable, the price of a recent transaction for an identical asset provides evidence of fair value as long as there has not been a significant change in economic circumstances or a significant lapse of time since the transaction took place. If the market is not active and recent transactions of an identical asset on their own are not a good estimate of fair value, the fair value is estimated by using a valuation technique.

2 Income from donations and legacies

	Unrestricted funds General £	Total funds £
Donations and legacies;		
Donations from individuals	29,633	29,633
Grants, including capital grants;		
Grants from other charities	75,000	75,000
Total for 2023	<u>104,633</u>	<u>104,633</u>
Total for 2022	<u>106,704</u>	<u>106,704</u>

3 Other income

	Unrestricted funds General £	Total funds £
Advocacy Fees	30,064	30,064
Total for 2023	<u>30,064</u>	<u>30,064</u>
Total for 2022	<u>30,371</u>	<u>30,371</u>

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2023 (continued)

4 Expenditure on charitable activities

	Note	Unrestricted funds General £	Total funds £
support of kidney cancer patients		100,339	100,339
Depreciation, amortisation and other similar costs		243	243
Total for 2023		<u>100,582</u>	<u>100,582</u>
Total for 2022		<u>87,212</u>	<u>87,212</u>

5 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

No trustees have received any reimbursed expenses or any other benefits from the charity during the year.

6 Taxation

The charity is a registered charity and is therefore exempt from taxation.

7 Tangible fixed assets

	Furniture and equipment £	Total £
Cost		
At 1 November 2022	<u>1,216</u>	<u>1,216</u>
At 31 October 2023	<u>1,216</u>	<u>1,216</u>
Depreciation		
At 1 November 2022	973	973
Charge for the year	<u>243</u>	<u>243</u>
At 31 October 2023	<u>1,216</u>	<u>1,216</u>
Net book value		
At 31 October 2023	<u>-</u>	<u>-</u>
At 31 October 2022	<u>243</u>	<u>243</u>

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2023 (continued)

8 Debtors

	2023 £	2022 £
Trade debtors	400	19,338
Prepayments	20,245	165
	<u>20,645</u>	<u>19,503</u>

9 Cash and cash equivalents

	2023 £	2022 £
Cash at bank	275,489	238,695

10 Creditors: amounts falling due within one year

	2023 £	2022 £
Trade creditors	7,210	3,330
Accruals	100	402
	<u>7,310</u>	<u>3,732</u>

11 Funds

	Balance at 1 November 2022 £	Incoming resources £	Resources expended £	Balance at 31 October 2023 £
Unrestricted				
General	<u>254,709</u>	<u>134,697</u>	<u>(100,582)</u>	<u>288,824</u>
	Balance at 1 November 2021 £	Incoming resources £	Resources expended £	Balance at 31 October 2022 £
Unrestricted				
General	<u>204,846</u>	<u>137,075</u>	<u>(87,212)</u>	<u>254,709</u>

Action Kidney Cancer

Notes to the Financial Statements for the Year Ended 31 October 2023 (continued)

12 Analysis of net assets between funds

	Unrestricted	Total funds
	General	2023
	£	£
Current assets	296,134	296,134
Current liabilities	(7,310)	(7,310)
Total net assets	<u>288,824</u>	<u>288,824</u>
	Unrestricted	Total funds
	General	2022
	£	£
Tangible fixed assets	243	243
Current assets	258,198	258,198
Current liabilities	(3,732)	(3,732)
Total net assets	<u>254,709</u>	<u>254,709</u>

Action Kidney Cancer

Detailed Statement of Financial Activities for the Year Ended 31 October 2023

	Total 2023 £	Total 2022 £
Income and Endowments from:		
Donations and legacies (analysed below)	104,633	106,704
Other income (analysed below)	<u>30,064</u>	<u>30,371</u>
Total income	<u>134,697</u>	<u>137,075</u>
Expenditure on:		
Charitable activities (analysed below)	<u>(100,582)</u>	<u>(87,212)</u>
Total expenditure	<u>(100,582)</u>	<u>(87,212)</u>
Net income	<u>34,115</u>	<u>49,863</u>
Net movement in funds	34,115	49,863
Reconciliation of funds		
Total funds brought forward	<u>254,709</u>	<u>204,846</u>
Total funds carried forward	<u><u>288,824</u></u>	<u><u>254,709</u></u>

Action Kidney Cancer

Detailed Statement of Financial Activities for the Year Ended 31 October 2023 (continued)

	Total 2023 £	Total 2022 £
<i>Donations and legacies</i>		
Appeals and donations	29,633	26,704
Grants - other agencies	75,000	80,000
	<u>104,633</u>	<u>106,704</u>
<i>Other income</i>		
Advocacy fees	30,064	30,371
	<u>30,064</u>	<u>30,371</u>
<i>Charitable activities</i>		
Rent	(660)	(495)
Insurance	12	(301)
Advocacy and medical relations	(28,314)	(25,439)
Telephone and fax	(168)	(201)
Communications	(11,185)	(10,380)
Office and administration	(8,657)	(6,441)
Website and maintenance	(7,744)	(7,914)
Patient Support	(14,750)	(16,260)
Sundry expenses	(240)	(4)
Conferences	-	(125)
Project management	(7,838)	(6,000)
Travel and subsistence	(1,087)	(161)
Marketing Material	(23)	(652)
Fundraising costs	(11,970)	(10,880)
Charity meeting	(5,071)	-
Accountancy fees	(100)	(100)
Legal and professional fees	(1,180)	(1,025)
All Giving platform charges	(1,364)	(591)
Depreciation of office equipment	(243)	(243)
	<u>(100,582)</u>	<u>(87,212)</u>